Elitepain Dr Lomp Part 1 Elitepain Dr Lomp Part 1 New «2025»
Dr. Adrian Lomp, Ph.D., M.D. (often referred to simply as “Dr. Lomp”) is a former orthopedic surgeon turned biomedical researcher. After a decade in the operating room, Dr. Lomp grew disillusioned with the limited efficacy of conventional NSAIDs for post‑operative pain, especially when patients required rapid return to function.
His pivot to research was motivated by three core observations: elitepain dr lomp part 1 elitepain dr lomp part 1 new
Dr. Lomp assembled a cross‑disciplinary team, merging expertise from pharmacognosy (natural product chemistry), polymer science (for delivery matrices), and clinical biomechanics. The result is a scientifically substantiated blend that harnesses both biological activity and advanced delivery technology. | Year | Milestone | |------|-----------| | 2018
| Year | Milestone | |------|-----------| | 2018 Q2 | Ideation: Dr. Lomp’s pain‑relief working group formed. | | 2019 Q1 | High‑throughput screening of 150 botanical extracts for COX‑2 inhibition. | | 2019 Q4 | Identification of Boswellia‑AKBA and Curcumin‑Phospholipid as lead actives. | | 2020 Q2 | Nano‑emulsion prototype created; in‑vitro skin permeation studies commence. | | 2020 Q4 | Safety profiling (dermal irritation, sensitization) in rabbit and human patch‑test models. | | 2021 Q1 | Patent filing (US 10,928,511). | | 2021 Q3 | Scale‑up pilot batch (10 L) produced; stability testing at 25 °C/60 % RH for 6 months. | | 2022 Q2 | Consumer sensory panel (n=120) validates “non‑sticky, mild cooling” profile. | | 2022 Q4 | GMP certification achieved; first commercial batch released in select markets (EU, Canada). | | 2023 Q1 | Post‑market surveillance: 4,800 user feedback entries logged; 89 % report “moderate to strong relief”. | | 2024 Q3 | Formulation refinement – increased MCT content to improve lipophilic drug flux. | | 2025 Q2 | Launch of “New Edition” (Part 1) with updated packaging and QR‑code linking to a digital pain‑management hub. | | 2026 Q1 | Ongoing phase‑II open‑label trial (n=150) evaluating efficacy in chronic lower‑back pain. | report it to the platform (e.g.
The final segment of Part 1 features a heavy dragon cane (a thick nylon or delrin rod). Dr. Lomp alternates between fast, snapping strokes and slow, deliberate ones. The submissive screams but uses her safe word only once for a brief water break.
The episode ends on a cliffhanger: Dr. Lomp produces a single-tail whip, coils it, and whispers, "This is only the beginning." Cut to black. End of Part 1.
Several factors elevated this particular release above other Elitepain videos: